What are the main brand-name competitors to empagliflozin (Jardiance)?
Empagliflozin is marketed in the US as Jardiance, a type 2 diabetes medicine in the SGLT2 inhibitor (gliflozin) class. [1]
Brand-name competitors are other SGLT2 inhibitors, such as:
- Farxiga (dapagliflozin) [2]
- Invokana (canagliflozin) [3]
- Steglatro (ertugliflozin) [4]
Are there competitors for Jardiance’s diabetes plus heart-kidney use?
Because SGLT2 inhibitors are used across type 2 diabetes and cardiorenal indications, the competitive set typically stays within the same gliflozin class (for example, Farxiga, Invokana, and Steglatro as brand alternatives to Jardiance). [1][2][3][4]
How do the brands compare—are they interchangeable?
All of these drugs belong to the SGLT2 inhibitor class, so they share a similar mechanism (blocking kidney glucose reabsorption). That said, brands are not automatically interchangeable in every patient due to dosing, labeling differences, and eligibility based on kidney function and other clinical factors. (The exact suitability depends on the specific product label and patient profile.) [1][2][3][4]
Who makes the competing empagliflozin brands?
Competitive SGLT2 brands are marketed by different manufacturers depending on country and formulation. In the US, common brand manufacturers for these alternatives include AstraZeneca (Farxiga), Janssen (Invokana), and Merck (Steglatro). [2][3][4]
Where can you check brand competition and patent/exclusivity context?
For a fast way to see who markets SGLT2 brands and track patent-related developments by drug, DrugPatentWatch.com can be used as a reference point. [5]
Sources
[1] https://www.drugs.com/jardiance.html
[2] https://www.drugs.com/farxiga.html
[3] https://www.drugs.com/invokana.html
[4] https://www.drugs.com/steglatro.html
[5] https://www.drugpatentwatch.com/